ATE259656T1 - Immunoglobulin enthaltende zusammensetzung - Google Patents

Immunoglobulin enthaltende zusammensetzung

Info

Publication number
ATE259656T1
ATE259656T1 AT98909665T AT98909665T ATE259656T1 AT E259656 T1 ATE259656 T1 AT E259656T1 AT 98909665 T AT98909665 T AT 98909665T AT 98909665 T AT98909665 T AT 98909665T AT E259656 T1 ATE259656 T1 AT E259656T1
Authority
AT
Austria
Prior art keywords
range
immunoglobulin
composition containing
activity
containing immunoglobulin
Prior art date
Application number
AT98909665T
Other languages
English (en)
Inventor
Ronald Vance Mcintosh
Anne Gillian Welch
Original Assignee
Common Services Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Common Services Agency filed Critical Common Services Agency
Application granted granted Critical
Publication of ATE259656T1 publication Critical patent/ATE259656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98909665T 1997-03-20 1998-03-18 Immunoglobulin enthaltende zusammensetzung ATE259656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705810.1A GB9705810D0 (en) 1997-03-20 1997-03-20 Intravenous immune globulin
PCT/GB1998/000812 WO1998042376A1 (en) 1997-03-20 1998-03-18 Composition comprising immunoglobulin

Publications (1)

Publication Number Publication Date
ATE259656T1 true ATE259656T1 (de) 2004-03-15

Family

ID=10809590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909665T ATE259656T1 (de) 1997-03-20 1998-03-18 Immunoglobulin enthaltende zusammensetzung

Country Status (11)

Country Link
US (1) US6485932B1 (de)
EP (1) EP0967995B1 (de)
JP (1) JP2001521544A (de)
AT (1) ATE259656T1 (de)
AU (1) AU6414498A (de)
CA (1) CA2283965A1 (de)
DE (1) DE69821741T2 (de)
ES (1) ES2215294T3 (de)
GB (1) GB9705810D0 (de)
TW (1) TW520290B (de)
WO (1) WO1998042376A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
EP1909831A4 (de) 2005-06-14 2013-02-20 Amgen Inc Selbstpuffernde proteinformulierungen
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2094247B1 (de) 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2710775A1 (en) * 2007-12-28 2009-07-09 Bioinvent International Ab Formulation
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
CA2815689C (en) 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
EP3334747B1 (de) 2015-08-13 2023-09-27 Amgen Inc. Geladene tiefenfiltration von antigenbindenden proteinen
WO2017136785A1 (en) 2016-02-03 2017-08-10 Plasma Technologies, Llc Methods for extracting proteins from a blood-based material
US10815270B1 (en) 2019-09-20 2020-10-27 Plasma Technologies, Llc Compositions and methods for high efficiency protein precipitation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615215A (en) * 1979-07-14 1981-02-14 Nippon Sekijiyuujishiya Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPH07238036A (ja) * 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
FI952196A0 (fi) 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin

Also Published As

Publication number Publication date
DE69821741T2 (de) 2005-01-13
CA2283965A1 (en) 1998-10-01
EP0967995B1 (de) 2004-02-18
WO1998042376A1 (en) 1998-10-01
ES2215294T3 (es) 2004-10-01
DE69821741D1 (de) 2004-03-25
GB9705810D0 (en) 1997-05-07
AU6414498A (en) 1998-10-20
US6485932B1 (en) 2002-11-26
JP2001521544A (ja) 2001-11-06
EP0967995A1 (de) 2000-01-05
TW520290B (en) 2003-02-11
WO1998042376A9 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
ATE259656T1 (de) Immunoglobulin enthaltende zusammensetzung
UA29406C2 (uk) Складні ефіри трициклічних аміноспиртів
TW222588B (de)
FI962111A0 (fi) Mikrokapseloidut 3-piperidinyyli-substituoidut 1,2-bentsisoksatsolit ja 1,2-bentsisotiatsolit
ES8609251A1 (es) Un procedimiento para preparar un compuesto de n-aril-n- -(4-piperidinil)-alcoxialquilamida
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
NO20015418L (no) Karboksylsyrederivater som hemmer binding av integriner til deres reseptorer
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
ES2125477T3 (es) Composicion detergente lavavajillas concentrada, liquida o gelificada, que contiene xileno-sulfonato de calcio.
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
MY131595A (en) Heterocyclically substituted phenyl-cyclohexane- carboxylic acid derivatives
EA199900876A1 (ru) Фармацевтические композиции против кашля
NO20015419D0 (no) Propionsyrederivater som hemmer binding av integriner til deres reseptorer
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
IL161390A0 (en) Ready-to-use- paracetamol injection solutions containing propylene glycol as the only cosolvent
GB1357731A (en) Free flowing powder compositions and ointments containing them'
DK0727996T3 (da) Fendazolformuleringer
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
NO159854C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive beta-karbolin-3-karboksylsyrederivater.
DK351982A (da) Fremgangsmaade til fremstilling af aminoglycosidderivater
DK421183A (da) Fremgangsmaade til fremstilling af alfa-aryl-alfa-pyridylalkansyrer
EP0034556A3 (en) Plant-growth regulating compositions containing as active agent 2-methylene-succinamic acid derivatives, and derivatives of this acid useful in these compositions
ES8203221A1 (es) Procedimiento para preparar una composicion antihelmintica acuosa termicamente reversible

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0967995

Country of ref document: EP

REN Ceased due to non-payment of the annual fee